Articles Tập 67 Số CĐ14-HNKH Hội Hóa sinh Y học Việt Nam 19/09/2026

THE ASSOCIATION BETWEEN PREOPERATIVE TSH LEVELS AND THE RISK OF PAPILLARY THYROID CARCINOMA

Pham Thi Minh Huyen, Dao Nguyen Khanh Linh, Ngo Quynh Diep, Diem Thi Phuong Thao, Ta Thanh Xuan, Nguyen Cam Thanh
DOI: 10.52163/yhc.v67iCD14.6461
0 Views
0 Downloads
Abstract

     Thyroid cancer is a common malignancy worldwide, with papillary thyroid carcinoma being the predominant type.

Objective: This study aimed to investigate the role of preoperative plasma TSH levels in the diagnosis of papillary thyroid carcinoma.

Subjects and Methods: The study included 336 patients with thyroid nodules, comprising 282 patients with papillary thyroid carcinoma and 54 patients with benign thyroid nodules. Preoperative plasma TSH levels were measured using an electrochemiluminescence immunoassay.

Results: The median TSH level in the papillary thyroid carcinoma group was 1.62 (1.09–2.35) µIU/mL, which was significantly higher than that in the benign nodule group [0.98 (0.77–1.85) µIU/mL (p = 0.001, Mann-Whitney test). The TI-RADS 5 group exhibited significantly higher TSH levels compared to the TI-RADS 3 and 4 groups. ROC analysis evaluating the diagnostic value of PTC based on the combination of preoperative TSH levels and TI-RADS scores yielded an area under the curve of 0.89, with a sensitivity of 0.85 and a specificity of 0.8.

Conclusion: Elevated preoperative plasma TSH levels correlate with an increased risk of thyroid cancer as indicated by ultrasound and histopathological findings. Preoperative TSH levels may serve as a useful supplementary biomarker for the diagnosis of papillary thyroid carcinoma.

Keywords
thyroid nodule, papillary thyroid carcinoma, TSH.
References
[1]
1. Boucai L, Zafereo M, ME C. Thyroid Cancer: A Review. JAMA. 2024;331(5):425-35. Google Scholar
[2]
2. Tessler FN, Middleton WD, Grant EG, al.ACR e. Thyroid Imaging, Reporting andData System (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587-95. Google Scholar
[3]
3. Polyzos SA, and Anastasilakis. Clinical complications following thyroid fine-needle biopsy: a systematic review. Clinical Endocrinology. 2009;71:157-65. Google Scholar
[4]
4. Rossi ED, Adeniran AJ, WC F. Pitfalls in Thyroid Cytopathology. Surg Pathol Clin. 2019;12(4):865-81. Google Scholar
[5]
5. Fiore E, P V. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. The Journal of Clinical Endocrinology and Metabolism. 2012;97(4):1134-45. Google Scholar
[6]
6. Golbert L, De Cristo AP, Faccin CS, al e. Serum TSH levels as a predictor of malignancy in thyroid nodules: a prospective study. PLoS One. 2017;12(e0188123–12). Google Scholar
[7]
7. Demircioglu ZG, Demircioglu MK, Aygun N, al e. Relationship Between Thyroid-Stimulating Hormone Level and Aggressive Pathological Features of Papillary Thyroid Cancer. Sisli Etfal Hastan Tip Bul. 2022;56(1):126-31. Google Scholar
[8]
8. Huang H, Rusiecki J, Zhao N, al e. Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study. Cancer Epidemiology, Biomarkers & Prevention 2017;26(8):1209-18. Google Scholar
[9]
9. Al Dawish MA, Robert AA, Muna A, al e. Bethesda System for Reporting Thyroid Cytopathology: A three-year study at a tertiary care referral center in Saudi Arabia. World J Clin Oncol. 2017;8(2):151-7. Google Scholar
[10]
10. Kaliszewski K, Diakowska D, Rzeszutko M, Nowak Ł, Wojtczak B, Sutkowski K, et al. Assessment of Preoperative TSH Serum Level and Thyroid Cancer Occurrence in Patients with AUS/FLUS Thyroid Nodule Diagnosis. Biomedicines. 2022;10(8):1916. Google Scholar